The coronavirus disease 2019 (COVID‐19) pandemic has entered its endemic phase and we observe significantly declining infection fatality rates due to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). On this background, it is crucial but challenging to define current and future vaccine policy in a population with a high immunity against SARS‐CoV‐2 conferred by previous infections and/or vaccinations. Vaccine policy must consider the magnitude of the risks conferred by new infection(s) with current and evolving SARS‐CoV‐2 variants, how these risks vary in different groups of individuals, how to balance these risks against the apparently small, but existent, risks of harms of vaccination, and the cost–benefit of different options. More evidence from randomized controlled trials and continuously accumulating national health data is required to inform shared decision‐making with people who consider vaccination options. Vaccine policy makers should cautiously weight what vaccination schedules are needed, and refrain from urging frequent vaccine boosters unless supported by sufficient evidence.

Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS‐CoV‐2 in the endemic phase?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037911

Elchanan Parnassa

Papers

Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel